VE of Nirsevimab (jags model w/ commensurate priors)

Date: 2024-08-13

Take a look at data extracted from previous trials and longitudinal studies

• Hammitt et al.2022: MELODY (Phase III)
• Simões et al. 2023: phase IIb + phase III
• Ares-Gómez et al. 2024: longitudinal study in Spain

Use the same set of confounders as in the main analysis

confounders_infection <- c(
  "age_at_test_in_months_cat_2", # 3-month interval
  "month_when_tested_cat"
)

confounders_ed <- c(
  "age_at_test_in_months_cat_2", # 3-month interval
  "month_when_tested_cat"
)

confounders_inpatient <- c(
  "age_at_test_in_months_cat_2", # 3-month interval
  "month_when_tested_cat",
  "risk_factor_atleastone"
)

confounders_severe <- c(
  "age_at_test_in_months_cat_2", # 3-month interval
  "month_when_tested_cat",
  "risk_factor_atleastone"
)

confounders_LRTI <- c(
  "age_at_test_in_months_cat_2", # 3-month interval
  "month_when_tested_cat",
  "risk_factor_atleastone"
)

confounders_LRTIhosp <- c(
  "age_at_test_in_months_cat_2", # 3-month interval
  "month_when_tested_cat",
  "risk_factor_atleastone"
)

Use data from previous trials as priors to do VE estimation

Comparing:
* Original trial estimates; * Adjusted VE estimated from current case-control study (uninformative priors); * Adjusted VE estimated from current case-control study (trial data as informative priors)

Medically attended RSV LRTI (Hammitt et al)

• extracted from case-control: RSV+ LRTI as cases vs. RSV- LRTI as controls

RSV-related LRTI hospitalizations (Hammitt et al)

• extracted from case-control: RSV-related LRTI hospitalizations as cases vs. RSV- as controls

Medically attended all-cause LRTI (Hammitt et al)

• extracted from case-control: records with LRTI symptoms as cases vs. those without LRTI symptoms as controls

RSV-related respiratory hospitalizations (Hammitt et al)

• extracted from case-control: RSV-positive hospitalizations as cases vs. RSV- as controls

Compare the results